Novartis’ Cosentyx (secukinumab) has failed to show any benefit in the Phase III study in adults with newly diagnosed or relapsing giant cell arteritis (GCA). In the GCAptAIN trial (NCT04930094), ...

Novartis announced top-line results from the phase III GCAptAIN study evaluating Cosentyx (secukinumab) in adults with newly diagnosed or relapsing giant cell arteritis (GCA). In the study, Cosentyx ...

“While the phase 3 results of GCAptAIN did not replicate the positive outcomes observed in the phase 2 trial, we remain committed to continuing to drive scientific progress and deepening the ...

NVS' Cosentyx fails to meet its primary goal in a phase III study for giant cell arteritis, despite favorable safety data.

Novartis today announced top-line results from the Phase III GCAptAIN study evaluating Cosentyx® (secukinumab) in adults with newly diagnosed or relapsing giant cell arteritis (GCA).

Both regulatory-approved and pipeline treatments for moderate to severe hidradenitis suppurativa demonstrate comparable ...

Sonelokimab, adalimumab, lutikizumab, and bimekizumab are the top-rated treatments for moderate-to-severe HS, a network ...

IL-17 inhibitors secukinumab and brodalumab demonstrate similar efficacy in patients with psoriasis for up to a year after dose spacing, according to a retrospective cohort study.

Objectives To investigate patient characteristics predictive of response to secukinumab in patients with psoriatic arthritis (PsA) with axial manifestations.Methods In a post-hoc analysis from the ...

A new study links abdominal fat, especially in women, to increased risk of psoriasis, regardless of genetic predisposition, ...

Objectives To explore 6-month and 12-month secukinumab effectiveness in patients with axial spondyloarthritis (axSpA) overall, as well as across (1) number of previous biologic/targeted synthetic ...